<DOC>
	<DOCNO>NCT00908141</DOCNO>
	<brief_summary>RATIONALE : Colony stimulate factor , GM CSF , may increase number immune cell find bone marrow peripheral blood . It yet know GM-CSF regimen effective treat patient prostate cancer . PURPOSE : This randomized phase II trial study well GM-CSF work treat patient relapsed prostate cancer .</brief_summary>
	<brief_title>GM-CSF Treating Patients With Relapsed Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine ability sargramostim ( GM-CSF ) increase number activation dendritic cell ( DC ) patient biochemically relapsed prostate cancer . Secondary - To determine effect administration schedule hormonal state sargramostim-induced DC number activation patient . - To correlate effect sargramostim DC number activation effect prostate-specific antigen ( PSA ) modulation . - To determine whether sargramostim administration generates antiprostate cancer immune responses patient . OUTLINE : Patients stratify accord hormonal status ( androgen-dependent v androgen-independent ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive sargramostim ( GM-CSF ) subcutaneously ( SC ) day 1-14 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive GM-CSF SC three time weekly 4 week . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients undergo blood sample collection periodically correlative study . Samples analyze dendritic cell ( DC ) number flow cytometry , DC activation quantitative real-time polymerase chain reaction ( QRT-PCR ) , immunity serological analysis recombinant cDNA expression library ( SEREX ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Nonmetastatic , recurrent systemic disease manifest rise PSA , define ≥ 2 consecutive rise PSA document reference value ( measure 1 ) The first rise PSA ( measure 2 ) take ≥ 14 day reference value A third confirmatory PSA measure require ( second beyond reference level ) great second , must obtain ≥ 14 day second measure If case , fourth PSA require take great second measure No localonly relapse Must undergone prior definitive therapy prostate cancer consist external beam radiotherapy , brachytherapy ( without external beam radiotherapy ) , radical prostatectomy ( without adjuvant androgen ablation ) Patients undergone definitive therapy undergone hormonal therapy alone eligible No evidence metastases bone CT scan PATIENT CHARACTERISTICS : ECOG performance status 01 Leukocytes ≥ 3,000/μl Absolute neutrophil count ≥ 1,500/μl Platelets ≥ 100,000/μl Total bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN No active thrombophlebitis disseminate intravascular coagulopathy No history pulmonary embolus No history immunodeficiency autoimmune diseases No uncontrolled intercurrent illness , include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior systemic chemotherapy reason No concurrent anticoagulation therapy ( i.e. , therapeutic coumadin ) Prophylactic anticoagulation ( e.g. , aspirin ) allow No concurrent systemic corticosteroid immunosuppressive Inhaled topical steroid allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>